- Home
- SATL vs CMRX Comparison
SATL vs CMRX Comparison
Compare SATL & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- CMRX
- Stock Information
- Founded
- SATL 2010
- CMRX 2000
- Country
- SATL Uruguay
- CMRX United States
- Employees
- SATL N/A
- CMRX N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- SATL Technology
- CMRX Health Care
- Exchange
- SATL Nasdaq
- CMRX Nasdaq
- Market Cap
- SATL 91.1M
- CMRX 80.7M
- IPO Year
- SATL N/A
- CMRX 2013
- Fundamental
- Price
- SATL $1.01
- CMRX $0.88
- Analyst Decision
- SATL
- CMRX Strong Buy
- Analyst Count
- SATL 0
- CMRX 1
- Target Price
- SATL N/A
- CMRX $11.00
- AVG Volume (30 Days)
- SATL 45.4K
- CMRX 126.0K
- Earning Date
- SATL 10-29-2024
- CMRX 11-04-2024
- Dividend Yield
- SATL N/A
- CMRX N/A
- EPS Growth
- SATL N/A
- CMRX N/A
- EPS
- SATL N/A
- CMRX N/A
- Revenue
- SATL $13,719,000.00
- CMRX $144,000.00
- Revenue This Year
- SATL N/A
- CMRX $3,040.12
- Revenue Next Year
- SATL N/A
- CMRX N/A
- P/E Ratio
- SATL N/A
- CMRX N/A
- Revenue Growth
- SATL 101.51
- CMRX N/A
- 52 Week Low
- SATL $0.69
- CMRX $0.75
- 52 Week High
- SATL $2.52
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- SATL 50.18
- CMRX 48.19
- Support Level
- SATL $0.97
- CMRX $0.80
- Resistance Level
- SATL $1.02
- CMRX $0.91
- Average True Range (ATR)
- SATL 0.04
- CMRX 0.04
- MACD
- SATL 0.00
- CMRX -0.00
- Stochastic Oscillator
- SATL 52.94
- CMRX 50.80
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.